


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claim 1 (currently amended): A compound having the following formula I:




wherein:

‘X’ represents an α -amino acid group wherein the α -amino group of the amino acid is bound to the $\text{R}_1\text{-O-CO-}$ group and the carboxy group of the amino acid is bound to the $\text{R}_2\text{-CH}_2\text{-CO-(CH}_2\text{)}_n\text{-CH(CO}_2\text{H)-NH-}$ group;

‘n’ is an integer between 1 and 4;

‘ R_1 ’ represents benzyl, t-butyl or 9-fluorenylmethyl; and

‘ R_2 ’ represents



wherein R_3 , R_4 , R_5 and R_6 each independently represent lower alkyl or $\text{-S}^+\text{R}_7\text{R}_8$, wherein R_7 and R_8 each independently represent lower alkyl or a pharmaceutically and/or veterinarily acceptable salt or solvate derivative thereof.


Claim 2 (original): A compound according to Claim 1 wherein X is an *L*-amino acid group.

Claim 3 (currently amended): A compound according to Claim 1 wherein X is selected from the group consisting of phenylalanine, glutamine ~~(or an N-substituted derivative thereof)~~, isoleucine, alanine, glycine, tyrosine, proline, serine, lysine and glutamic acid.

Claim 4 (previously presented): A compound according to claim 1 wherein 'n' is 2.

Claim 5 (previously presented): A compound according to claim 1 wherein R₁ is benzyl.


Claim 6 (previously presented): A compound according to claim 1 wherein R₂ represents



Claim 7 (currently amended): A ~~compounds~~ compound according to claim 1 wherein R₂ represents $-S^+R_7R_8$, wherein R₇ and R₈ each independently represent lower alkyl.


Claim 8 (currently amended): A compound according to claim 1 wherein R₃, R₄, R₅, R₆, R₇ and/or R₈ are C₁ to C₃ alkyl ~~-CH₃ or -CHCH₃~~.

Claim 9 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 10 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 11 (currently amended): A compound according to Claim 1 having the following formula:



or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.


Claim 12 (currently amended): A compound according to Claim 1 having the following formula:



or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.


Claim 13 (canceled)

Claim 14 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 15 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 16 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 17 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 18 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 19 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 20 (currently amended): A compound according to Claim 1, wherein the compound is *N*- α -Benzyloxycarbonyl-*N*- ϵ -trifluoroacetate-*L*-lysiny-6-dimethylsulfonium-5-oxo-*L*-norleucine or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof, having the following formula:




Claim 21 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 22 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 23 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 24 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 25 (currently amended): A compound according to Claim 1 having the following formula:




or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 26 (currently amended): A compound according to Claim 1 having the following formula:



or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 27 (currently amended): A compound according to Claim 1 having the following formula:



or a pharmaceutically and/or veterinarily acceptable salt or solvate thereof.

Claim 28 (previously presented): A compound according to claim 1 in the form of a bromide salt.

Claim 29 (previously presented): A pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

Claim 30 (previously presented): A method for making a compound according to claim 1 comprising the following steps:

- (a) reacting an *N*- α -protected amino acid *N*-hydroxy-succinimide or *para*-nitrophenyl ester with 6-diazo-5-oxo-L-norleucine, and treating the resulting coupled product with hydrogen bromide; and
- (b) reacting the bromomethyl ketone produced in step (a) with dimethyl sulphide, diethyl sulphide or 1,3,4,5-tetra-methyl mercapto-imidazoline-2-thione.

Claim 31 (original): A method according to Claim 30 wherein the *N*- α -protected amino acid *N*-hydroxysuccinimide ester is CBZ, FMOC or BOC protected.

Claim 32 (previously presented): A method according to Claim 30 wherein step (a) comprises reacting an *N*- α -protected amino acid *N*-hydroxy-succinimide or *para*-nitrophenyl ester

with 6-diazo-5-oxo-L-norleucine in the presence of tetrahydrofuran (THF), water and triethylamine followed by reacting the products thereof with hydrogen bromide in the presence of ethyl acetate.

Claim 33 (currently amended): A method according to Claim [[31]] 30 wherein the *N*- α -CBZ-protected amino acid *N*-hydroxy-succinimide ester is selected from the group consisting of *N*- α -CBZ-*L*-phenylalanine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-glutamine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-isoleucine *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-alanine
~~alanine~~ *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-glycine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-proline *N*-hydroxy-succinimide ester, *N*- α -CBZ-*L*-serine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-tyrosine *N*-hydroxysuccinimide ester, *N*- α -CBZ-*L*-glutamic acid *N*-hydroxysuccinimide ester, and
N- α -CBZ-*L*-lysine *N*-hydroxysuccinimide ester ~~and *N*- α -CBZ-*L*-tyrosine *para*-nitrophenyl ester.~~

Claims 34-36 (canceled)

Claim 37 (currently amended): A method for treating a patient suffering from a disease/disorder selected from the group consisting of fibrosis, scarring, neurodegenerative diseases, autoimmune diseases, thrombosis, proliferative disorders, AIDS, psoriasis, cancer, ~~fibrosis, scarring~~
and inflammation ~~(such as chronic inflammatory diseases)~~, the method comprising administering to the patient a composition comprising the compound of Claim 1.

Claim 38 (currently amended): The ~~[[use]]~~ method according to ~~Claims 35~~ Claim 37 wherein the ~~medicament is for treating~~ disease/disorder is cancer.

Claims 39-40 (canceled)

Claim 41 (currently amended): A method for treating a patient to prevent or treat rejection of a transplanted organ, the method comprising administering to the patient a composition comprising a compound of Claim 1.

Claim 42 (previously presented): The method of Claim 41 wherein the organ is a heart, lung, kidney or liver.

Claim 43 (previously presented): The method of Claim 41 wherein the organ is treated prior to transplantation.

Claim 44 (currently amended): The method of ~~Claims~~ Claim 41 wherein the organ is treated during and/or after transplantation into a patient.

Claim 45 (new): The method of Claim 37, wherein the disease is a chronic inflammatory disease.